**SUPPLEMENT**

Supplement Figure 1. Seroconversion percentage of PCR positive individuals shown as seroconversion with antibody to nucleocapsid (N), receptor binding domain (RBD), and overall seroconversion in any assay. N=130. Of 14 SARS-CoV-2 RT-PCR positive individuals who did not seroconvert by the N assay, ten had seroconverted on the RBD assay. Seven SARS-CoV-2 RT-PCR positive individuals did not seroconvert by the RBD assay, of whom three were seropositive by the N assay. Statistical analysis comparing seropositivity by N assay and RBD assay using McNemar’s test p=0.096.

|  |  |  |  |
| --- | --- | --- | --- |
| GISAID\_accession | Lineage | Sequencing platform | Care Home |
| EPI\_ISL\_465388 | B.1 | Illumina HiSeq | G |
| EPI\_ISL\_526757 | B.1 | Illumina HiSeq | G |
| EPI\_ISL\_528408 | B.2.1 | Illumina HiSeq | A |
| EPI\_ISL\_528409 | B.2.1 | Illumina HiSeq | A |
| EPI\_ISL\_528410 | B.2.1 | Illumina HiSeq | A |
| EPI\_ISL\_527358 | B.2.1 | Illumina HiSeq | A |
| EPI\_ISL\_465484 | B.1 | Illumina HiSeq | F |
| EPI\_ISL\_465485 | B.1 | Illumina HiSeq | F |
| EPI\_ISL\_528411 | B.1 | Illumina HiSeq | F |
| EPI\_ISL\_526771 | B.1.1 | Illumina NextSeq | F |
| EPI\_ISL\_465487 | B.1.1 | Illumina NextSeq | F |
| EPI\_ISL\_465488 | B.1.1 | Illumina NextSeq | F |
| EPI\_ISL\_526772 | B.1 | Illumina HiSeq | F |
| EPI\_ISL\_465547 | B.1.1 | Illumina HiSeq | D |
| EPI\_ISL\_465548 | B.1.1 | Illumina HiSeq | D |
| EPI\_ISL\_528413 | B.1 | Illumina HiSeq | F |
| EPI\_ISL\_465579 | B.1 | Illumina HiSeq | F |
| EPI\_ISL\_465594 | B.1.1 | Illumina HiSeq | D |
| EPI\_ISL\_528415 | B.1.1 | Illumina HiSeq | D |
| EPI\_ISL\_526545 | B.2.1 | Illumina NextSeq | C |
| EPI\_ISL\_528394 | B.1.5 | Illumina HiSeq | E |

Supplement Table 1. GISAID accession numbers, lineage assignment (generated using <https://pangolin.cog-uk.io/>, sequencing platform and care home identifier of the successfully sequenced viruses detailed in **Figure 4.**